Precystectomy Nomogram for Prediction of Advanced Bladder Cancer Stage{A figure is presented}

European Urology

Volumn 50, Issue 6, 2006, Pages 1254-1262

  Karakiewicz, Pierre I ^a   Shariat, Shahrokh F ^b   Palapattu, Ganesh S ^c   Perrotte, Paul ^a   Lotan, Yair ^b   Rogers, Craig G ^c   Amiel, Gilad E ^d   Vazina, Amnon ^d   Gupta, Amit ^b   Bastian, Patrick J ^c   Sagalowsky, Arthur I ^b   Schoenberg, Mark ^c   Lerner, Seth P ^d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bladder cancer; Cystectomy; Grade; Nomogram; Prediction; Stage

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CARCINOMA IN SITU; CONTROLLED STUDY; CYSTECTOMY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NOMOGRAM; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; SEX DIFFERENCE; SURGICAL PATIENT; TRANSURETHRAL RESECTION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; CYSTECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; URINARY BLADDER NEOPLASMS;

EID: 33750617349     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.06.010     Document Type: Article

References (21)

1. Dutta S.C., Smith Jr. J.A., Shappell S.B., Coffey C.S., Chang S.S., and Cookson M.S. Clinical under staging of high-risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166 (2001) 490-493
2. Van Der Meijden A., Sylvester R., Collette L., Bono A., and Ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials. J Urol 164 (2000) 1533-1537
3. Stein J.P. Indications for early cystectomy. Urology 62 (2003) 591-595
4. Bianco Jr. F.J., Justa D., Grignon D.J., Sakr W.A., Pontes J.E., and Wood Jr. D.P. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 22 (2004) 290-294
5. Soloway M.S., Lopez A.E., Patel J., and Lu Y. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer 73 (1994) 1926-1931
6. Pagano F., Bassi P., Galetti T.P., et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 145 (1991) 45-50
7. Harrell Jr. F.E., Lee K.L., and Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 28 (1996) 361-387
8. Bradley E., and Tibshirani R.J. Monographs on statistics and applied probability: an introduction to the bootstrap (1993), Champman and Hall/CRC, Boca Raton
9. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162 (1999) 74-76
10. Brauers A., Buettner R., and Jakse G. Second resection and prognosis of primary high-risk superficial bladder cancer: Is cystectomy often too early?. J Urol 165 (2001) 808-810
11. Ooms E.C., Anderson W.A., Alons C.L., Boon M.E., and Veldhuizen R.W. Analysis of the performance of pathologists in the grading of bladder tumors. Hum Pathol 14 (1983) 140-143
12. Sharkey F.E., and Sarosdy M.F. The significance of central pathology review in clinical studies of transitional cell carcinoma in situ. J Urol 157 (1997) 68-70
13. Coblentz T.R., Mills S.E., and Theodorescu D. Impact of second opinion pathology in the definitive management of patients with bladder carcinoma. Cancer 91 (2001) 1284-1290
14. Liedberg F., and Mansson W. Lymph node metastasis in bladder cancer. Eur Urol 49 (2006) 13-21
15. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-475
16. Shariat S.F., Zippe C., Ludecke G., et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 173 (2005) 1518-1525
17. Graefen M., Karakiewicz P.I., Cagiannos I., et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 20 (2002) 3206-3212
18. Sorbellini M., Kattan M.W., Snyder M.E., et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173 (2005) 48-51
19. Kattan M.W., Leung D.H., and Brennan M.F. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 20 (2002) 791-796
20. Specht M.C., Kattan M.W., Gonen M., Fey J., and Van Zee K.J. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 12 (2005) 654-659
21. Graefen M., Ohori M., Karakiewicz P.I., et al. Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol 171 (2004) 200-203